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Antwerp University Hospital, Thoracic Oncology /MOCA, Edegem, BelgiumApproximately one third of patients with non-small-celllung cancer (NSCLC) present with resectable disease, defined
as clinical stages I and II and some borderline stage III exten-
sions (e.g. T3N0–1). Although radical resection is the corner-
stone of treatment in adequately staged patients, its
outcome is not always curative, as some patients might be
functionally inoperable, refuse surgery, have an unexpected
non-radical resection or stage upgrading, or relapse locally
or with distant metastases. The following reviews address
the current state of the art in the peri- and intra-operative
management of patients with resectable NSCLC.
As disease extent is an important predictor of prognosis
and determines treatment choices, accurate staging is of
prime importance. The 10 modifications and the mediastinal
lymph-node map – adopted by the American Joint Committee
on Cancer (AJCC) and the Union for International Cancer Con-
trol (IUCC) in their respective seventh revision of the tumour-
node-metastasis (TNM) system – are considered a quality indi-
cator for disease extent, initial treatment allocation and the
reporting of treatment results. Difficulties arise in accurate
prognosis owing to the role of stagemigration and the increas-
ing number of biological factors interfering with disease ex-
tent. There are many tumour-related pathological factors,
but only one is actually routinely used in clinical practice.
Most factors probably lack potential clinical usefulness.
Surgical resection remains the standard of care for func-
tionally operable early-stage NSCLC and resectable stage IIIA
disease. The role of invasive staging and restaging techniques
is currently under debate, but they provide large biopsy spec-
imens which allow for precise mediastinal staging. Different
operative procedures are currently available to the thoracic
surgeon, and some can be performed by video-assisted tho-
racic surgery (VATS) with oncological results equal to those
of open thoracotomy.
The new multidisciplinary adenocarcinoma classification
has profound surgical implications. The role of limited or
sublobar resection comprising anatomical segmentectomy
andwidewedgeresectionareconsideredforearly-stage lesionswhich are more frequently encountered with the recently
introduced screening programmes. Large databases are cur-
rently collectingmanysurgical parameters, allowingmorepre-
cise calculation of mortality and morbidity according to
predefined risk factors. Centralisation of care has been shown
to improve results. Quality-of-life evaluation is becoming
increasingly important and should be consideredwhen decid-
ing on a specific treatment, especially in a multimodality
setting.
In the situation of totally resected NSCLC patients, the role
of post-operative chemotherapy is now established for stages
II and IIIA and remains debatable in stage IB. Various at-
tempts to identify prognostic biomarkers for selecting pa-
tients for adjuvant chemotherapy have failed so far. Patient
selection for adjuvant therapy should be based upon more
discriminatory pathological data than a crude assessment
such as stage, but only if supported by evidence. The present
recommendations for resected NSCLC from the European
Society for Medical Oncology (ESMO) are to deliver a cis-
platin-based chemotherapy for stages II and III. The role of
post-operative radiation therapy (PORT) in this group of pa-
tients remains controversial. In a meta-analysis, the conclu-
sions were that PORT was detrimental to patients with
early-stage completely resected NSCLC, but the role of PORT
in the treatment of tumours with N2 involvement was un-
clear, and further research was warranted. Recent retrospec-
tive and non-randomised studies – as well as subgroup
analyses of randomised trials evaluating adjuvant chemo-
therapy – provide evidence of possible benefit of PORT in pa-
tients with mediastinal nodal involvement.
In summary, these are exciting times for the treatment of
early-stage lung cancer as prevalence, classification, staging
and treatment have changed, although proof of better out-
come has still to be delivered.
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